Biocon (BIOCON) Fundamentals 2026 — P/E 157.0x, Revenue Analysis | SniperIQ
Biocon (BIOCON) is a India-listed Healthcare company in Biotechnology with a market capitalization of ₹59,864 Crore, trading at ₹437.95 on the BSE. This SniperIQ fundamentals page covers Biocon's valuation (P/E 157.0x, P/B 2.1x), profitability (net margin 2.3%), revenue (₹16,927 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Biocon's market cap?
Biocon (BIOCON) has a market capitalization of approximately ₹59,864 Crore, trading at ₹437.95 on the BSE. Market cap moves with the live share price.
What is Biocon's P/E ratio?
Biocon's trailing twelve-month P/E ratio is 157.0x, with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Biocon?
Biocon runs a net profit margin of 2.3%, a gross margin of 50.0%, and an operating margin of 16.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Biocon generate?
Biocon reported revenue of ₹16,927 Crore for fiscal year 2026, with net income of ₹386 Crore and earnings per share (EPS) of 2.82. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Biocon pay a dividend?
Biocon offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Biocon financially healthy?
Biocon carries a debt-to-equity ratio of 0.45x and a current ratio of 1.22x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Biocon a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Biocon (BIOCON) the key facts are: market cap ₹59,864 Crore, P/E 157.0x, revenue ₹16,927 Crore, 52-week range 331-447. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Biocon's full fundamentals live
Get Biocon's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.